32 results about "Uncoupling Agents" patented technology

An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

The invention discloses a method for producing methane through anaerobic digestion of high-solid content sludge, belonging to the technical field of sludge treatment. The method comprises the steps of regulating the carbon nitrogen ratio of a treatment object, namely the dehydrated high-solid content sludge of a municipal sewage treatment plant, carrying out intermediate temperature pretreatment, adding inoculated sludge in a proportion, then adding waste scrap iron, rhamnolipid, alkyl polyglucoside, 3,3,4,5-tetrachlorosalicylanilide (TCS) and the like in a phased manner, turning and stirring at regular intervals, controlling the temperature at 34-38 DEG C, and carrying out anaerobic digestion. After the high-solid content sludge is treated, the internal mass transfer efficiency of the sludge is increased in the anaerobic digestion process, and the yield of methane is increased. Medicament materials used in the method include production waste, a biodegradable surfactant and a low-toxicity chemical uncoupling agent, so that the production of the methane through the anaerobic digestion of the high-solid content sludge can be effectively promoted, the environmental risk is reduced, and the utilization degrees of the recycling and energy regeneration of the sludge are increased.

The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present invention further relates to methods for identifying new compounds that have respiration uncoupling activity.

The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD⁺ levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

The invention provides methods for screening for agents that modulate mitochondrial function and in particular mitochondrial regulation of intracellular calcium. The methods may be used to detect agents that bind to a mitochondrial calcium uniporter and may also detect inhibitors or uncouplers of mitochondrial respiration. Agents identified using the screens provided herein have application in the prevention and treatment of a variety of diseases associated with abnormal mitochondrial function.

The invention relates to the field of plant disease control, in particular to application of amitriptyline as a bactericide synergist in plant disease control. The occurrence of oomycete disease resistance to fungicides and even multi-drug resistance in the field is reported, resistance including an uncoupling agent is often associated with the multi-drug resistance, the management of such resistant groups is very difficult, and great harm is brought to agricultural production. According to the application of amitriptyline as the bactericide synergist in plant disease control, the amitriptyline and a diarylamine bactericide, substituted benzene bactericides or piperidinothiazole isoxazoline bactericides, are found to have good synergism on the combined toxicity of phytophthora resistant mutants after being mixed, the toxicity of the bactericides can be effectively improved, the sensitivity of drug resistant strains to the bactericides is restored, the usage amount of the bactericides is reduced, and a new method is provided for the development and application of new preparations of existing bactericides. The application provides a new application of farm chemical, can be used for disease control in the agricultural field, and provides a new way for disease resistance management in the field.

The present invention provides a method capable of substantially reducing the sludge amount in sludge treatment. According to the method, the filler for filling the biological carrier in the sewage treatment main process is rich in a variety of trace elements for microorganism growth, the unique form of the biological carrier can form the DO changeable environment, the sludge retention time (SRT) is long, the variety is rich, the food chain is long, and the newly-generated sludge is progressively re-degraded by a variety of microorganisms so as to achieve the sludge reduction purpose. According to the present invention, the sludge generation amount of the sewage treatment process is reduced to 0.1-0.15% of the sewage amount from 0.8-1% of the sewage amount, the uncoupling agent adding is not required, no secondary pollution is generated, the variety and the quantity of the microorganisms can be easily controlled, the control is easy, the effect is significant, the application range is wide, the method can be used for treating municipal wastewater, park wastewater, industrial wastewater, domestic wastewater and other organic wastewater, the operating is stable, the changes of the hydropower and the water quality can be bore, and the adjust workload is low.

The invention belongs to the fields of biology and medicine and discloses a method for generating mitochondria uncoupling and activating adenosine monophosphate activated protein kinase (AMPK). The method is characterized in that horizontal reversed electron transfer of a mitochondrial respiratory chain complex I is caused by oxidation of a sulfur-containing compound through SQR, cross-mitochondrial inner membrane potential is reduced, and thereby mitochondrial uncoupling is generated; by the mitochondrial uncoupling, the synthesis level of ATP in cells can be reduced and further the AMPK is activated. The invention also discloses a method for obtaining a mitochondria uncoupling agent and an AMPK activator based on the SQR. The experiment verifies that the method disclosed by the inventionhas the advantages that firstly, oxidation of the sulfur-containing compound by the SQR is a novel method for generating the mitochondria uncoupling or activating the AMPK; secondly, a novel mitochondria uncoupling agent or the AMPK activator can be obtained on the basis of the SQR; thirdly, an obtained compound has the mitochondria uncoupling of cell specificity or AMPK activating effect as wellas low toxic and side effects, and can be used for treating related diseases.

The invention relates to a composite uncoupling agent for reducing excess sludge in a sewage treatment process by an activated sludge method, which comprises the following components: 3,3,4,5-tetrachloro salicylamide, soluble copper salt and an adsorbent, wherein the soluble copper salt is one of copper sulfate, copper chloride or copper acetate; the adsorbent is one of refined diatomite or zeolite powder or a mixture of the refined diatomite and the zeolite powder; the weight ratio of the 3,3,4,5-tetrachloro salicylamide to the soluble copper salt is 1:0.05-0.25; and the weight ratio of the total of the 3,3,4,5-tetrachloro salicylamide and the soluble copper to the adsorbent is 1:0.05-1.00. The composite uncoupling agent has obvious positive effect, particularly stronger sludge reductionperformance. If the same weight reduction rate of the sludge is achieved, the added TCS (tetrachloro salicylamide) can be reduced by 25 to 75 percent, and after the TCS is added into a system, the removing rate of the COD (chemical oxygen demand) is basically not influenced.

The invention provides a pharmaceutical composition used for preventing or treating metabolism or damage-related diseases. The pharmaceutical composition comprises at least one mitochondrial uncoupling agent and at least one artemisinin compound; and the pharmaceutical composition can effectively and remarkably improve symptoms of polydipsia, polyphagia and polyuria of diabetes, reduces various metabolic indexes related to blood glucose and insulin, reduces metabolic disorders brought by insulin defects, relieves islet damage or insulin resistance, exerts a protective effect on kidneys, can effectively prevent or treat diabetic nephropathy and kidney damage related diseases, meanwhile, has certain protection and improvement effects on liver damage and lipid metabolism, can effectively adjust and stabilize the body temperature, and takes effect quickly.

The invention discloses a pyridine phenyl coupling compound and a pharmaceutical composition and application thereof. The pyridine phenyl coupling compound is a PSD-95-nNOs uncoupling agent, can selectively inhibit combination between PSD-95 and nNOs to achieve the pharmaceutical effect, has the important potential treatment effect and has wide application in preparation of drugs for treating stroke, neuropathic pain and an alzheimer disease or vascular dementia.

The invention discloses a compound uncoupling agent which is used for deweighting treatment of residual sludge in the sewage treatment technology with the activated sludge process. The compound uncoupling agent comprises 3,3,4,5-tetrachlorosalicylamide, refined diatomite and zeolite. When one part by weight of 3,3,4,5-tetrachlorosalicylamide is provided, 0.05-1.0 part by weight of refined diatomite is provided, and 0.05-1.0 part by weight of zeolite is provided. The compound uncoupling agent provided by the invention can obviously lower attenuation on sludge activity while keeping favorable sludge decrement performance and has obvious active effect, which embodies on the aspect that the sludge decrement performance is enhanced, for example, the added TCS can be reduced by 20-60% for reaching the same sludge decrement ratio; after TCS is added in a system, COD strainaway rate is not affected on the whole.

The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

The present invention relates to an organophosphonium derivative of the mean general formula (1), where n is a number comprised between 4 and 20, preferably between 5 and 10, m is a number between 0 and 10, preferably between 0 and 1, and Y is an anion.

The invention also relates to a method for preparing same, and to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to said aqueous system or contacting said aqueous system with an efficient amount of an uncoupling agent selected from an organophosphonium derivative as defined above.

The disclosure provides compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, R4, R5, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. The disclosure includes pharmaceutical composition comprising a compound or salt Formula I, and apharmaceutically acceptable carrier. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as obesity, cancer, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.